Last update: 3 August 2012
The regulatory body for approval of medicines in Canada is the Therapeutic Products Directorate of Health Canada.
Health Canada develops and enforces regulations under Canadian governmental legislation.
Last update: 3 August 2012
The regulatory body for approval of medicines in Canada is the Therapeutic Products Directorate of Health Canada.
Health Canada develops and enforces regulations under Canadian governmental legislation.
Health Canada applies the Food and Drug Regulations under the authority of the Food and Drugs Act to ensure that the pharmaceutical drugs offered for sale in Canada are safe, effective and of high quality.
The Canadian Food & Drugs Act and Regulations were amended in 1995 in order to allow for a generics manufacturer to file an Abbreviated New Drug Submission (ANDS). This allows:
An ANDS typically requires bioequivalence, chemistry & manufacturing and/or pharmaceutical equivalence data to be submitted, but does not require preclinical data, which is normally required for an originator drug.
Canada has the following guidelines for generic medicines:
1. Overarching Guideline
This guideline covers all generic products:
Notice - Integrated Review of Abbreviated New Drug Submissions (ANDSs)
Date: 1 October 2007
http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/notice_ands_rev_avis_padn_pro-eng.pdf
2. General Guidelines
These guidelines cover all generic products:
Quality Overall Summary – Chemical Entities (New Drug Submissions/Abbreviated New Drug Submissions) (QOS-CE [NDS/ANDS])
Date: 1 April 2004
http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/qoscendsands_sgqecpdnpadn-eng.pdf
Draft Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs)
Date: 18 July 2001
http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/qual_ndsands_pdnpadn_07-01-eng.pdf
Related article
Canadian guidelines for biosimilars
Source: Health Canada
DIGEMID: aprobaciones automáticas en 45 días disparan advertencias sobre seguridad
Regulación de biosimilares en Argentina: el enfoque de ANMAT
China-to-West pharma licensing deals surge in 2024 amid innovation push
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Canadá se dispone a eliminar el requisito de ensayos de fase III para los biosimilares
Un nuevo decreto promueve los medicamentos biosimilares fabricados en Argentina
Avances en los planes de la EMA para agilizar la evaluación de biosimilares
Actualización normativa para el post-registro de productos biológicos en Brasil
Post your comment